Back
G11
G11 Resources Limited
🇦🇺 ASX
⛏️ MINING
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-5.86%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
G11 Resources Ltd. engages in the exploration of mineral resources. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-08-05. The Company’s Koonenberry Project is an emerging, district scale, copper, nickel, and other base metals exploration package located 80 kilometers (km) east of Broken Hill, New South Wales. The emerging, district scale, Copper and Base Metals Koonenberry project has three advanced, highly prospective areas; Grasmere, Cymbric Vale and Wertago that the Company is actively exploring. The Koonenberry Project covers 3,300 square kilometers (km2) of land holding, containing over 200km of strike of the significantly under-explored Koonenberry Belt. The Koonenberry Belt is a northern continuation of the Cambrian Delamerian Orogen, situated between the Curnamona Province to the west, and the Thomson Orogen to the east. The Wilandra Corridor is a 75km stretch of the Koonenberry Belt which is prospective for polymetallic mineralization. The Wertago Prospect is located 40km north of the Wilandra Corridor.
📈 Performance
Price History
-41.43%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.02
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in G11
1
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
8 weeks
💵 Average investment amount
$1,135
⏰ Last time a customer invested in G11
6 days
G11 investor breakdown
💵 Income of investors
More than 200k
50%
150k - 200k
100k - 150k
50k - 100k
Less than 50k
50%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in G11 also invest in...
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.88%
📊 Share price
$149.10 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
23.40%
📊 Share price
$66.70 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
CSL
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
🙌 Performance (5Yr p.a)
-5.96%
📊 Share price
$198.34 AUD
⚖️ HIGH GOVERNANCE
🕊️ SOCIALLY AWARE
🧬 BIOTECHNOLOGY
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.04%
📊 Share price
$109.59 AUD
🧱 MATERIALS
💸 FINANCIALS
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
Want more shares? Try these...
